Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
Ever Evaluation of SIL-204 in Clinically Relevant Orthotopic Models; Analysis Underway with Initial Results Expected in ...
Part of a series to inform nuclear facility designers, vendors, operators and State governments about IAEA safeguards and how associated requirements can be considered early in the design phase of a ...
In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with a price target of $9.00. The company’s shares ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion Therapeutics” or the "Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for ...
Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...
(MENAFN- GlobeNewsWire - Nasdaq) Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the“Company”), a ...
Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC) Across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback